戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 l pulp tissues, are potential tools for cell transplantation therapy.
2 permeability and immune-protection for islet transplantation therapy.
3 , may impose two major barriers in LCAs cell transplantation therapy.
4 ay provide an alternative to donor lungs for transplantation therapy.
5  and targeted injection of MSCs can optimize transplantation therapy.
6 ction represents a promising new approach to transplantation therapy.
7 ecome a prominent and pervasive influence on transplantation therapy.
8  that is crucial to the effectiveness of the transplantation therapy.
9 beneficial to improve the outcomes for islet transplantation therapy.
10 ntial for clinical application of liver cell transplantation therapy.
11 possibilities for in vitro research and cell transplantation therapy.
12 derlie beta cell failure and/or hamper islet transplantation therapy.
13 ood should make them valuable candidates for transplantation therapy.
14 help combat the severe shortage of donors in transplantation therapy.
15  of ex vivo expanded hematopoietic cells for transplantation therapy.
16  represent a promising site for future islet transplantation therapy.
17 of this strategy into clinics as a bridge-to-transplantation therapy.
18 prove the safety of future hPSC-derived cell transplantation therapies.
19  in vitro that are needed for autologous HSC transplantation therapies.
20 erlies the curative capacity of clinical HSC transplantation therapies.
21 fering with BTLA signaling in post-stem cell transplantation therapies.
22 afe source of endodermal-derived tissues for transplantation therapies.
23 , providing an unlimited source of cells for transplantation therapies.
24 otropic liver transplantation and hepatocyte transplantation therapies.
25 creen and toxicity testing, and for cellular transplantation therapies.
26 ns ranging from in vitro diagnostics to cell transplantation therapies.
27 em (hES) cells offer the opportunity for new transplantation therapies.
28  the hydrogel as potential cell carriers for transplantation therapies.
29 n and suggest a potential role for stem cell transplantation therapies.
30 , as a source of human DA neurons for use in transplantation therapies.
31  a novel source of cells for transfusion and transplantation therapies.
32 ifferentiation and may play a role in future transplantation therapies.
33  unlimited supply of specific cell types for transplantation therapies.
34 f an optochemogenetics approach in stem cell transplantation therapy after stroke for optimal neural
35 ncements are made in hematopoietic stem cell transplantation therapies and extracorporeal membrane ox
36 que opportunity to improve patient access to transplantation therapies and to offer more patients the
37 d opportunity to generate new beta-cells for transplantation therapy and drug screening.
38 logies, is a promising approach for cellular transplantation therapy and for in vitro disease modelin
39                                   Fetal cell transplantation therapies are being developed for the tr
40 s to create patient-specific donor cells for transplantation therapy, avoiding immunorejection, a maj
41 e development of future dopamine neuron cell transplantation therapy-based approaches, indicating tha
42 ion about the use of totipotent ESCs in cell transplantation therapy, because they may act as an unan
43  unlimited source of cells suitable for such transplantation therapy can be derived from embryonic st
44 e quest for more precise and effective organ transplantation therapies, chimeric antigen receptor (CA
45 n this review we examine how stem cell-based transplantation therapies compare with these novel and e
46 genitor cells (NPC) represent potential cell transplantation therapies for CNS injuries.
47                   The hope of developing new transplantation therapies for degenerative diseases is l
48 enhance the efficiency of both gene and cell transplantation therapies for hepatic diseases.
49  the design of stem or progenitor cell-based transplantation therapies for HIV infection.
50 new avenues for basic research and potential transplantation therapies for neurological diseases.
51 s the development of personalized iPSC-based transplantation therapies for retinal disease.
52                Approaches to successful cell transplantation therapies for the injured brain involve
53 ial damage, which suggests their use in cell transplantation therapy for cardiomyopathy.
54 ells will need to be identified if effective transplantation therapy for chronic pain is to be develo
55                                              Transplantation therapy for human diabetes is limited by
56 R-HLA mismatching in hematopoietic stem cell transplantation therapy for leukemia and new, more speci
57 Despite advances in stem cell research, cell transplantation therapy for liver failure is impeded by
58                      UCB increases access to transplantation therapy for many patients unable to iden
59 em cells enables standardized and autologous transplantation therapy for PD.
60  to successful allogeneic hematopoietic cell transplantation therapy for the treatment of hematologic
61                Stem cell-based regenerative (transplantation) therapies for PD have not been implemen
62 y mAb has been used for immunosuppression in transplantation, therapy for leukemia, and autoimmune di
63 come an important tool for devising new cell transplantation therapies, generating disease models and
64 great success including those awaiting liver transplantation, therapy has been extended to patients w
65  hematopoietic cell culture technologies for transplantation therapies have progressed significantly
66                                              Transplantation therapies have revolutionized care for p
67 l role of human embryonic stem (ES) cells in transplantation therapy have often overshadowed their po
68 opments in the application of stem cells for transplantation therapies in neurodegenerative diseases.
69 e for the future application of hES cells in transplantation therapies in which the use of aneuploid
70 nted cell source for drug discovery and cell transplantation therapy in diabetes.
71 oach for enhancing the effectiveness of cell transplantation therapy in ischaemic stroke.
72 ukin 6 facilitates the effectiveness of cell transplantation therapy in ischaemic stroke.
73 afe approach to enhance the effectiveness of transplantation therapy in ischemic stroke.
74  Noonan syndrome and for improving stem cell transplantation therapy in Noonan-syndrome-associated le
75       We review recent advances in bridge-to-transplantation therapy, including the use of a paracorp
76           Human mesenchymal stem cell (hMSC) transplantation therapy is a promising approach, althoug
77 lterations in synapse count before and after transplantation therapy of FOXG1 progenitors in vivo.
78 tial hinderance to the use of such cells for transplantation therapy of insulin-dependent diabetes me
79 resent an alternative to isolated islets for transplantation therapy of type 1 diabetes.
80                This may have applications in transplantation therapy or in the treatment of diseased
81 a strategy for extending the availability of transplantation therapy, particularly for older patients
82                                         Cell transplantation therapy provides a regenerative strategy
83                                  Bone marrow transplantation therapy relies on the life-long regenera
84 nt quality of care including access to renal transplantation therapy (RTT).
85 py for chronic liver diseases or after liver transplantation, therapy should be continued at the lowe
86                         As a prerequisite to transplantation therapy, strategies must be developed to
87 believed to be superior to Schwann cells for transplantation therapies to treat CNS injuries.
88 iption factor TWIST1 for an efficacious cell transplantation therapy to induce neovascularization-med
89        World Kidney Day is a call to deliver transplantation therapy to the 1 million people a year w
90  may also improve the chances for successful transplantation therapy via earlier reinduction therapy,